

Generic Health Pty Ltd

ACN: 110 617 859

**Annual report for the
financial year ended 31 March 2025**

Table of contents	Page
Directors' report	3
Auditor's independence declaration	5
Independent Auditor's Report	6
Directors' declaration	9
Consolidated statement of profit or loss and other comprehensive income	10
Consolidated statement of financial position	11
Consolidated statement of changes in equity	12
Consolidated statement of cash flows	13
Notes to the financial statements	14

Directors' report

The directors of Generic Health Pty Ltd (the "company") submit herewith the annual financial report of Generic Health Pty Ltd and its controlled entities (collectively, "the consolidated entity") for the financial year ended 31 March 2025. In order to comply with the provisions of the *Corporations Act 2001*, the directors report as follows:

The names of the directors of the company during or since the end of the financial year are:

Name

Sofia Mumtaz	Chairman
Ashutosh Damle	Executive Director
Sunil Makharia	Director
Fabrice Egros	Director
Sudarshan Menon	Company Secretary

The above named directors and officers held office during and since the end of the financial year unless otherwise stated.

Principal activities

The consolidated entity's principal activities in the course of the financial year were the registration and wholesale distribution of generic pharmaceutical products within Australia. During the year a new subsidiary, Lupin NZ Ltd, has been setup to initiate distribution of pharmaceutical products in New Zealand. Nanomi B.V. (incorporated and domiciled in the Netherlands) is the company's parent entity and Lupin Limited (incorporated and domiciled in India) is the company's ultimate parent entity.

No significant change in the nature of these activities occurred during the financial year.

Review of operations

The consolidated profit for the year after providing for income tax amounted to \$ 14,853,212 (2024: consolidated profit of \$13,263,172).

Changes in state of affairs

There was no significant changes of in the state of affairs of the consolidated entity.

Future developments

Disclosure of information regarding likely developments in the operations of the consolidated entity in future financial years and the expected results of those operations is likely to result in unreasonable prejudice to the consolidated entity. Accordingly, this information has not been disclosed in this report.

Environmental regulations

The operations of the consolidated entity are not subject to significant environmental regulations. To the best of the directors' knowledge, all activities are performed in accordance with the requirements of relevant environmental regulations.

Subsequent Events

No matter or circumstance has occurred subsequent to year end that has significantly affected, or may significantly affect, the operations of the Company, the results of those operations or the state of affairs of the entity in subsequent financial years.

Dividends

No dividends were paid or declared since the start of the financial year. No recommendation for payment of dividends has been made.

Share options

No options over issued shares or interests in the consolidated entity were granted during or since the end of the year.

Directors' report (cont'd)

Indemnification of officers and auditors

During the financial year, the company paid a premium in respect of a contract insuring the directors and officers of the company and of any related body corporate against a liability incurred as such a director or officer to the extent permitted by the *Corporations Act 2001*. The contract of insurance prohibits disclosure of the nature of the liability and the amount of the premium.

The company has not otherwise, during or since the financial year ended 31 March 2025, indemnified or agreed to indemnify the auditor of the company or of any related body corporate against a liability incurred as such an officer or auditor.

Proceedings on behalf of the company

No person has applied for leave of Court to bring proceedings on behalf of the company or intervened in any proceedings to which the company is a party for the purpose of taking responsibility on behalf of the company for all or any part of those proceedings.

The company was not a party to any such proceedings during the financial year.

Auditor's independence declaration

The auditor's independence declaration is included on page 5 of the annual report.

Signed in accordance with a resolution of directors made pursuant to s.298(2) of the *Corporations Act 2001*.

On behalf of the Directors

Ashutosh Damle
Director
Melbourne, 6 May 2025



Lead Auditor's Independence Declaration under Section 307C of the Corporations Act 2001

To the Directors of Generic Health Pty Ltd

I declare that, to the best of my knowledge and belief, in relation to the audit of Generic Health Pty Ltd for the financial year ended 31 March 2025 there have been:

- i. no contraventions of the auditor independence requirements as set out in the *Corporations Act 2001* in relation to the audit; and
- ii. no contraventions of any applicable code of professional conduct in relation to the audit.

KPMG

Amanda Bond

Partner

Melbourne

6 May 2025



Independent Auditor's Report

To the shareholders of Generic Health Pty Ltd

Report on the audit of the Financial Report

Opinion

We have audited the **Financial Report** of Generic Health Pty Ltd (the Company).

In our opinion, the accompanying Financial Report of the Company gives a true and fair view, including of the **Group's** financial position as at 31 March 2025 and of its financial performance for the year then ended, in accordance with the *Corporations Act 2001*, in compliance with *Australian Accounting Standards - Simplified Disclosures* and the *Corporations Regulations 2001*.

The **Financial Report** comprises:

- Consolidated statement of financial position as at 31 March 2025
- Consolidated statement of profit or loss and other comprehensive income, Consolidated statement of changes in equity, and Consolidated statement of cash flows for the year then ended
- Notes, including material accounting policies
- Directors' Declaration.

The **Group** consists of the Company and the entities it controlled at the year end or from time to time during the financial year.

Basis for opinion

We conducted our audit in accordance with *Australian Auditing Standards*. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Our responsibilities under those standards are further described in the *Auditor's responsibilities for the audit of the Financial Report* section of our report.

We are independent of the Group in accordance with the *Corporations Act 2001* and the ethical requirements of the *Accounting Professional and Ethical Standards Board's APES 110 Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the Financial Report in Australia. We have fulfilled our other ethical responsibilities in accordance with these requirements.

Other Information

Other Information is financial and non-financial information in Generic Health Pty Ltd's annual report which is provided in addition to the Financial Report and the Auditor's Report. The Directors are responsible for the Other Information.

The Other Information we obtained prior to the date of this Auditor's Report was the Directors' report.

Our opinion on the Financial Report does not cover the Other Information and, accordingly, we do not express an audit opinion or any form of assurance conclusion thereon.

In connection with our audit of the Financial Report, our responsibility is to read the Other Information. In doing so, we consider whether the Other Information is materially inconsistent with the Financial Report or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

We are required to report if we conclude that there is a material misstatement of this Other Information, and based on the work we have performed on the Other Information that we obtained prior to the date of this Auditor's Report we have nothing to report.

Responsibilities of the Directors for the Financial Report

The Directors are responsible for:

- preparing the Financial Report in accordance with the *Corporations Act 2001*, including giving a true and fair view of the financial position and performance of the Group, and in compliance with *Australian Accounting Standards -Simplified Disclosures* and the *Corporations Regulations 2001*
- implementing necessary internal control to enable the preparation of a Financial Report in accordance with the *Corporations Act 2001*, including giving a true and fair view of the financial position and performance of the Group, and that is free from material misstatement, whether due to fraud or error
- assessing the Group and Company's ability to continue as a going concern and whether the use of the going concern basis of accounting is appropriate. This includes disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless they either intend to liquidate the Group and Company or to cease operations, or have no realistic alternative but to do so.

Auditor's responsibilities for the audit of the Financial Report

Our objective is:

- to obtain reasonable assurance about whether the Financial Report as a whole is free from material misstatement, whether due to fraud or error; and
- to issue an Auditor's Report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with *Australian Auditing Standards* will always detect a material misstatement when it exists.

Misstatements can arise from fraud or error. They are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Financial Report.



A further description of our responsibilities for the audit of the Financial Report is located at the *Auditing and Assurance Standards Board* website at: https://www.auasb.gov.au/media/apzlwn0y/ar3_2024.pdf. This description forms part of our Auditor's Report.

KPMG

Amanda Bond

Partner

Melbourne

6 May 2025

Directors' declaration

The directors declare that:

- (a) in the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable; and
- (b) in the directors' opinion, the attached financial statements and notes thereto are in accordance with the *Corporations Act 2001*, including:
 - (i) giving a true and fair view of the financial position as at 31 March 2025 and performance of the company for the year ended on that date; and
 - (ii) complying with Accounting Standards – Simplified Disclosure and *Corporations Act 2001*.

Signed in accordance with a resolution of the directors made pursuant to s.295(5) of the *Corporations Act 2001*.

On behalf of the Directors

Ashutosh Damle
Director
Melbourne, 6 May 2025

**Consolidated statement of profit or loss and other comprehensive income
for the year ended 31 March 2025**

	Note	Consolidated	
		2025	2024
		\$	\$
Revenue	5	119,388,379	108,550,367
Cost of sales		(80,046,083)	(70,901,724)
Gross profit		39,342,296	37,648,643
Other income	5	1,833,714	630,798
Administration expense		(2,587,682)	(2,165,789)
Sales and marketing expense		(664,991)	(589,152)
Employee expense	4	(8,509,825)	(7,939,174)
Regulatory expense		(2,107,765)	(2,471,008)
Warehousing expense		(2,884,206)	(2,047,314)
Finance expense		(11,500)	(18,519)
Depreciation & amortisation		(3,083,886)	(3,509,617)
Profit before tax		21,326,155	19,538,868
Income tax expense	22	(6,472,943)	(6,275,696)
Profit for the year	4	14,853,212	13,263,172
Other comprehensive income		-	-
Total comprehensive income for the year		14,853,212	13,263,172

The accompanying notes form part of these financial statements.

Consolidated statement of financial position as at 31 March 2025

	Notes	Consolidated	
		2025	2024
		\$	\$
Current assets			
Cash and cash equivalents	21(a)	21,839,935	9,910,208
Trade and other receivables	6	19,804,394	22,443,968
Inventories	7	36,618,618	34,353,434
Other assets	8	847,543	2,944,662
Total current assets		79,110,490	69,652,272
Non-current assets			
Plant and equipment	10	91,176	75,186
Intangible assets	11	21,310,863	22,772,699
Right of use asset	12	219,072	370,106
Goodwill	9	10,269,000	10,269,000
Deferred tax assets	24	2,110,993	1,255,520
Total non-current assets		34,001,104	34,742,511
Total assets		113,111,594	104,394,783
Current liabilities			
Trade and other payables	13	17,865,926	22,008,001
Contract Liability	15	-	379,911
Lease liability	16	240,546	214,924
Provisions	17	1,311,513	1,281,962
Total current liabilities		19,417,985	23,884,798
Non-current liabilities			
Lease Liability	16	79,887	298,241
Other Financial Liability	15	400,000	1,200,000
Provisions	17	118,757	66,184
Deferred tax Liability	24	5,144,918	5,848,725
Total non-current liabilities		5,743,562	7,413,150
Total liabilities		25,161,547	31,297,948
Net assets		87,950,047	73,096,835
Equity			
Issued Capital	18	33,883,471	33,883,471
Accumulated Profits		54,066,576	39,213,364
Net assets		87,950,047	73,096,835

The accompanying notes form part of these financial statements.

**Consolidated statement of changes in equity
for the year ended 31 March 2025**

	Issued capital \$	Accumulated Profits \$	Total \$
Balance at 1 April 2023	33,883,471	25,950,192	59,833,663
Profit for the year	-	13,263,172	13,263,172
Other comprehensive income	-	-	-
Total comprehensive income for the year	-	13,263,172	13,263,172
Balance at 31 March 2024	33,883,471	39,213,364	73,096,835
Balance at 1 April 2024	33,883,471	39,213,364	73,096,835
Profit for the year	-	14,853,212	14,853,212
Other comprehensive income	-	-	-
Total comprehensive income for the year	-	14,853,212	14,853,212
Balance at 31 March 2025	33,883,471	54,066,576	87,950,047

The accompanying notes form part of these financial statements.

Consolidated statement of cash flows for the year ended 31 March 2025

	Consolidated	
	2025	2024
	\$	\$
Cash flows from operating activities		
Receipts from customers (including GST)	122,058,074	109,586,902
Settlement income	-	-
Interest received	1,033,714	630,798
Interest payment	(11,500)	(18,519)
Payment to employees and suppliers (including GST)	(101,123,373)	(100,766,032)
Income taxes paid	(8,347,594)	(15,260,757)
Net cash provided by / (used in) operating activities	13,609,321	(5,827,608)
Cash flows from investing activities		
Purchase of plant and equipment	(58,981)	(56,507)
Purchase of intangible assets (product development costs)	(1,395,661)	(993,306)
Net cash used in investing activities	(1,454,642)	(1,049,813)
Cash flows from financing activities		
Payments of deferred consideration	-	-
Deposits	-	5,000,000
Repayments of lease liabilities	(224,952)	(202,963)
Repayment of borrowings		(5,000,000)
Net cash used in financing activities	(224,952)	(202,963)
Net (decrease)/increase in cash held	11,929,727	(7,080,404)
Cash at the beginning of the financial year	9,910,208	9,565,982
Cash at the end of the financial year	21(a) 21,839,935	9,910,208

The accompanying notes form part of these financial statements.

1. General information

Generic Health Pty Ltd is a proprietary company limited by shares, incorporated and operating in Australia.

Nanomi B.V. (incorporated and domiciled in the Netherlands) is the company's parent and Lupin Limited (incorporated and domiciled in India) is the company's ultimate parent.

Generic Health Pty Ltd.'s registered office and principal place of business are as follows: Suite 2, Level 2, 19-23 Prospect Street, Box Hill, VIC

2. Adoption of new and revised Accounting Standards

2.1 Standards and Interpretations affecting amounts reported in the current period

The Company has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to their operations and effective for an accounting period that begins on or after 1 April 2024.

New and revised Standards and amendments thereof and Interpretations effective for the current year that are relevant to the Company include:

AASB 2020-3 Amendments to Australia Accounting Standards – Annual Improvements 2018-2020 and Other Amendments.

The application of the amendments did not have a material impact on the Groups consolidated financial statements, as the amendments either do not effect the Group's existing accounting policies, or apply to situations, transactions and events that the Group does not undertake.

3. Material accounting policies

Statement of compliance

These financial statements are general purpose financial statements which have been prepared in accordance with the *Corporations Act 2001* and Australian Accounting Standards – Simplified Disclosures and comply with other requirements of the law.

The financial statements comprise the consolidated financial statements of the Group. For the purposes of preparing the consolidated financial statements, the Company is a for-profit entity.

The financial statements were authorized for issue by the directors on 6 May 2025.

Basis of preparation

The consolidated financial statements have been prepared on the basis of historical cost, except for certain properties and financial instruments that are measured at revalued amounts or fair values at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair values of the consideration given in exchange for assets. All amounts are presented in Australian dollars, unless otherwise noted.

Historical cost is generally based on the fair values of the consideration given in exchange for goods and services. All amounts are presented in Australian dollars, unless otherwise noted.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

In addition, for financial reporting purposes, fair value measurements are categorized into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurements are observable and the significance of the inputs to the fair value measurement in its entirety.

Critical accounting judgments and key sources of estimation uncertainty

In the application of the consolidated entity's accounting policies the directors are required to make judgments, estimates and assumptions about carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognized in the period in which the estimate is revised if the revision affects only that period or in the period of the revision and future periods if the revision affects both current and future periods.

Areas where judgment has been used include the bad debt provision, the inventory provision, the useful lives of plant and equipment, the useful lives of intangible assets and the carrying value of product development costs, not yet available for use. See the relevant accounting policies for additional detail.

3. Material accounting policies (cont'd)

Critical accounting judgments and key sources of estimation uncertainty (continued)

Goodwill

Following the assessment of the recoverable amount of goodwill allocated to the “acquisition of Southern Cross Pharma” business to which goodwill of 10,269,000 is allocated, the Directors consider the customer contracts and the product approvals, as significant to the achievement of budget. Budgets comprise forecasts of revenue, staff costs and overhead costs based on current and anticipated market conditions. Revenue of the sector are stable in nature and the market has seen increased demand over the past couple of years. While reviewing the valuation of goodwill, the market growth has been considered to be negligible and projection are considered for a period of 5 years. Goodwill is not amortised but reviewed for impairment annually. For the purpose of impairment testing, goodwill is allocated to each of the Group’s cash-generating units (or groups of cash-generating units) expected to benefit from the synergies of the combination. Cash-generating units to which goodwill has been allocated are tested more frequently when there is an indication that the unit may be impaired. The cash generating units are valued using the net present value methodology. Sales and profit are estimated over a period of 5 years to ascertain the current value including the terminal value. If the recoverable amount of the cash-generating unit is less than the carrying amount of the unit, the impairment loss is allocated first to reduce the carrying amount of any goodwill allocated to the unit and then to the other assets of the unit pro-rata on the basis of the carrying amount of each asset in the unit. An impairment loss recognised for goodwill is not reversed in a subsequent period. On disposal of a cash-generating unit, the attributable amount of goodwill is included in the determination of the profit or loss on disposal.

Long service leave

Provisions made in respect of employee benefits which are not expected to be settled within 12 months are measured at the present value of the estimated future cash outflows to be made by the entity in respect of services provided by employees up to reporting date which includes assessing probabilities of employee retention and future wage and on-cost increases.

Plant and equipment

Useful lives and residual value of plant and equipment are reviewed annually. Judgement is applied in determining the useful lives of plant and equipment. Any reassessment of useful lives and residual value in a particular year will affect depreciation and amortisation expense (either increasing or decreasing) from the date of reassessment through to the end of the reassessed useful life for both the current and future years.

Provision for obsolete stock

Management’s judgement is applied in determining the provision for inventory obsolescence. If the estimated selling price of inventory is lower than the cost to sell, the difference is recognised in the provision for obsolescence.

Credit loss on trade receivables

The Group has elected to use the simplified approach, which requires the recognition of lifetime expected loss allowance for all trade receivables. Trade receivables have been grouped based on credit risks attributes and debtor’s days in estimating expected credit losses.

Recognition of deferred tax asset in respect of losses

The Group applies judgement in estimating the recognition of the recorded deferred tax asset with respect to previously unrecognised carry forward losses. The Group applies judgement in relation to the estimated future taxable profitability from which to realise the deferred tax asset.

Capitalised product development costs

At year end, the entity has recognised on its statement of financial position various expenditures that relate to the development of, and registration with the relevant authorities of, the products sold in the course of carrying on its business. These costs relate to licensing fees, bio equivalency studies, regulatory and other charges. The directors have applied a degree of judgement in the classification of these expenses to the extent that they are allowable under AASB 138. For those capitalised at year end, management have made the determination that these expenses meet the definition of an intangible asset, are probable that the expected future economic benefits attributable to the asset will flow to the entity and that the cost of the asset can be measured reliably. Refer Note (k) for further information.

(a) Principles of consolidation

The consolidated financial statements incorporate the financial statements of the Company and entities controlled by the Company and its subsidiaries. Control is achieved when the Company:

- has power over the investee;
- is exposed, or has rights, to variable returns from its involvement with the investee; and
- has the ability to use its power to affect its returns.

The Company reassesses whether or not it controls an investee if facts and circumstances indicate that there are changes to one or more of the three elements of control listed above.

3. Material accounting policies (cont'd)

(a) Principles of consolidation (cont'd)

When the Company has less than a majority of the voting rights of an investee, it has power over the investee when the voting rights are sufficient to give it the practical ability to direct the relevant activities of the investee unilaterally. The Company considers all relevant facts and circumstances in assessing whether or not the Company's voting rights in an investee are sufficient to give it power, including:

- the size of the Company's holding of voting rights relative to the size and dispersion of holdings of the other vote holders;
- potential voting rights held by the Company, other vote holders or other parties;
- rights arising from other contractual arrangements; and
- any additional facts and circumstances that indicate that the Company has, or does not have, the current ability to direct the relevant activities at the time that decisions need to be made, including voting patterns at previous shareholders' meetings.

Consolidation of a subsidiary begins when the Company obtains control over the subsidiary and ceases when the Company loses control of the subsidiary. Specifically, income and expenses of a subsidiary acquired or disposed of during the year are included in the consolidated statement of profit or loss and other comprehensive income from the date the Company gains control until the date when the Company ceases to control the subsidiary. Profit or loss and each component of other comprehensive income are attributed to the owners of the Company and to the non-controlling interests. Total comprehensive income of subsidiaries is attributed to the owners of the Company and to the non-controlling interests even if this results in the non-controlling interests having a deficit balance.

When necessary, adjustments are made to the financial statements of subsidiaries to bring their accounting policies into line with the entity's accounting policies. All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between members of the Group are eliminated in full on consolidation.

All intragroup assets and liabilities, equity, income, expenses and cash flows relating to transactions between the members of the Group are eliminated on consolidation.

When the entity loses control of a subsidiary, a gain or loss is recognised in profit or loss and is calculated as the difference between (i) the aggregate of the fair value of the consideration received and the fair value of any retained interest and (ii) the previous carrying amount of the assets (including goodwill), and liabilities of the subsidiary and any non-controlling interests. All amounts previously recognised in other comprehensive income in relation to that subsidiary are accounted for as if the entity had directly disposed of the related assets or liabilities of the subsidiary (i.e. reclassified to profit or loss or transferred to another category of equity as specified/permitted by applicable AASBs).

(c) Borrowings

All loans and borrowings are initially recognised at the fair value of the consideration received less directly attributable transaction costs.

After initial recognition, interest-bearing loans and borrowings are subsequently measured at amortised cost using the effective interest method. Fees paid on the establishment of loan facilities that are yield related are included as part of the carrying amount of the loans and borrowings.

Borrowings are classified as current liabilities unless the consolidated entity has an unconditional right to defer settlement of the liability for at least 12 months after the reporting date.

Borrowing costs

Borrowing costs directly attributable to the acquisition, construction or production of qualifying assets, which are assets that necessarily take a substantial period of time to get ready for their intended use or sale, are added to the cost of those assets, until such time as the assets are substantially ready for their intended use or sale. Investment income earned on the temporary investment of specific borrowings pending their expenditure on qualifying assets is deducted from the borrowing costs eligible for capitalisation.

All other borrowing costs are recognised in profit or loss in the period in which they are incurred.

(d) Financial instruments

Financial assets and financial liabilities are recognised when the Company becomes a party to the contractual provisions of the instrument. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss. Financial assets are classified as loans and receivables and financial liabilities are classified as other financial liabilities.

3. Material accounting policies (cont'd)

(d) Financial instruments (cont'd)

Effective Interest Method

The effective interest method is a method of calculating the amortised cost and of allocating interest income / (expense) over the relevant period. The effective interest rate is the rate that exactly discounts estimated future cash receipts / payments (including all fees on points paid or received that form an integral part of the effective interest rate, transaction costs and other premiums or discounts) through the expected life of the instrument, or (where appropriate) a shorter period, to the net carrying amount on initial recognition.

Loans and receivables

Financial assets are initially measured at fair value net of transactions costs. Financial assets consisting trade receivables, loans and other receivables that have fixed or determinable payments are measured subsequently at amortised cost at the effective interest method, less any expected credit losses given that:

- the financial asset is held within a business model whose objective is to hold financial assets in order to collect contractual cash flows; and
- the contractual terms of the financial asset give rise on specified dates to cash flows that are solely payments of principal and interest on the principal amount outstanding.

De-recognition of financial assets

The Company derecognises a financial asset when the contractual rights to the cash flows from the asset expire, or when it transfers the financial asset and substantially all the risks and rewards of ownership of the asset to another party. On de-recognition of a financial asset in its entirety, the difference between the asset's carrying amount and the sum of the consideration received and receivable and the cumulative gain or loss that had been recognised in other comprehensive income and accumulated in equity is recognised in profit or loss.

Other Financial liabilities

Other Financial liabilities, including borrowings and trade and other payables, are initially measured at fair value, net of transaction costs. Other financial liabilities are subsequently measured at amortised cost using the effective interest method, with interest expense recognised on an effective yield basis.

The Company derecognises financial liabilities when, and only when, the Company's obligations are discharged, cancelled or they expire. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

Derecognition of financial liabilities

The Group derecognises financial liabilities when, and only when, the Group's obligations are discharged, cancelled or have expired. The difference between the carrying amount of the financial liability derecognised and the consideration paid and payable is recognised in profit or loss.

(e) Cash and cash equivalents

Cash and cash equivalents comprise cash on hand, cash in banks and investments in money market instruments, net of outstanding bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities in the statement of financial position.

(f) Comparative amounts

Where required by Accounting Standards, comparative amounts have been adjusted to conform to changes in presentation in the current financial year.

(g) Employee benefits

Short term provision is made for benefits accruing to employees in respect of wages and salaries, annual leave, and long service leave when it is probable that settlement will be required and they are capable of being measured reliably.

Provisions made in respect of employee benefits expected to be settled within 12 months, are measured at their nominal values using the remuneration rate expected to apply at the time of settlement. Provisions made in respect of employee benefits which are not expected to be settled within 12 months are measured as the present value of the estimated future cash outflows to be made by the company in respect of services provided by employees up to reporting date.

3. Material accounting policies (cont'd)

(h) Foreign currency transactions

The financial statements of the Company are presented in the currency of the primary economic environment in which the entity operates (its functional currency). For the purpose of the financial statements, the results and financial position of the Company are expressed in Australian dollars ('\$'), which is the functional currency of the Company and the presentation currency for the financial statements.

In preparing the financial statements, transactions in currencies other than the entity's functional currency (foreign currencies) are recognised at the rates of exchange prevailing at the dates of the transactions. At the end of each reporting period, monetary items denominated in foreign currencies are retranslated at the rates prevailing at that date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing at the date when the fair value was determined. Non-monetary items that are measured in terms of historical cost in a foreign currency are not retranslated.

(i) Goods and Services Tax (GST)

Revenues, expenses and assets are recognised net of the amount of goods and services tax (GST), except:

- i. where the amount of GST incurred is not recoverable from the taxation authority, it is recognised as part of the cost of acquisition of an asset or as part of an item of expense;
or
- ii. for receivables and payables which are recognised inclusive of GST.

The net amount of GST recoverable from, or payable to, the taxation authority is included as part of receivables or payables.

Cash flows are included in the statement of cash flows on a gross basis. The GST component of cash flows arising from investing and financing activities which is recoverable from, or payable to, the taxation authority is classified as operating cash flows.

(j) Impairment of assets

At each reporting date, the company reviews the carrying amounts of its tangible and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Intangible assets with indefinite useful lives and intangible assets not yet available for use are tested for impairment annually and whenever there is an indication that the asset may be impaired.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised in profit or loss immediately, unless the relevant asset is carried at fair value, in which case the impairment loss is treated as a revaluation decrease.

Where an impairment loss subsequently reverses, the carrying amount of the asset (cash-generating unit) is increased to the revised estimate of its recoverable amount, but only to the extent that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (cash-generating unit) in prior years. A reversal of an impairment loss is recognised in profit or loss immediately, unless the relevant asset is carried at fair value, in which case the reversal of the impairment loss is treated as a revaluation increase.

(k) Impairment of property, plant and equipment and intangible assets excluding goodwill

At each reporting date, the Group reviews the carrying amounts of its property, plant and equipment and intangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated to determine the extent of the impairment loss (if any). Where the asset does not generate cash flows that are independent from other assets, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs. When a reasonable and consistent basis of allocation can be identified, corporate assets are also allocated to individual cash-generating units, or otherwise they are allocated to the smallest group of cash-generating units for which a reasonable and consistent allocation basis can be identified.

Intangible assets with an indefinite useful life are tested for impairment at least annually and whenever there is an indication at the end of a reporting period that the asset may be impaired.

3. Material accounting policies (cont'd)

(k) Impairment of property, plant and equipment and intangible assets excluding goodwill (cont'd)

Recoverable amount is the higher of fair value less costs of disposal and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted.

If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease and to the extent that the impairment loss is greater than the related revaluation surplus, the excess impairment loss is recognised in profit or loss.

Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss to the extent that it eliminates the impairment loss which has been recognised for the asset in prior years. Any increase in excess of this amount is treated as a revaluation increase.

(l) Income tax

Tax consolidation

Generic Health Pty Ltd and its resident wholly owned subsidiaries have notified the Australian Tax Office of their adoption of the tax consolidation regime. Tax expenses/income, deferred tax liabilities and deferred tax assets arising from temporary differences of the members of the tax-consolidated group are recognised in the separate financial statements of the members of the tax-consolidated group using the 'separate taxpayer within the group' approach by reference to the carrying amounts of assets and liabilities in the separate financial statements of each entity and the tax values applying under tax consolidation. Current Tax liabilities and assets and deferred tax assets arising from unused tax losses of the subsidiaries are recognised in the head entity, Generic Health Pty Ltd.

Entities within the tax consolidated group have not entered into a tax funding agreement and a tax-sharing agreement with the head entity. Any amount owing from head entity to ATO is satisfied with a loan from Generic Health Pty Ltd. Such amounts are reflected in amounts receivable or payable to the head entity. Southern Cross Pharma is part of the Tax consolidated group.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of profit or loss and other comprehensive income because of items of income or expense that are taxable or deductible in other years and items that are never taxable or deductible. The Group's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period. Adjustments are made for transactions and events occurring within the tax-consolidated group that do not give rise to a tax consequence for the Group or that have a different tax consequence at the level of the Group.

Deferred tax

Deferred tax is recognised on temporary differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable temporary differences. Adjustments are made for transactions and events occurring within the tax-consolidated group that do not give rise to a tax consequence for the Group or that have a different tax consequence at the level of the Group.

Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible temporary differences can be utilised. Such deferred tax assets and liabilities are not recognised if the temporary difference arises from goodwill or from the initial recognition (other than in a business combination) of other assets and liabilities in a transaction that affects neither the taxable profit nor the accounting profit.

Deferred tax liabilities are recognised for taxable temporary differences associated with investments in subsidiaries and associates, and interests in joint ventures, except where the company is able to control the reversal of the temporary difference and it is probable that the temporary difference will not reverse in the foreseeable future. Deferred tax assets arising from deductible temporary differences associated with such investments and interests are only recognised to the extent that it is probable that there will be sufficient taxable profits against which to utilise the benefits of the temporary differences and they are expected to reverse in the foreseeable future.

3. Material accounting policies (cont'd)

(l) Income tax (cont'd)

Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. The measurement of deferred tax liabilities and assets reflects the tax consequences that would follow from the manner in which the company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.

Deferred tax assets and liabilities are offset when there is a legally enforceable right to set off current tax assets against current tax liabilities and when they relate to income taxes levied by the same taxation authority and the company intends to settle its current tax assets and liabilities on a net basis.

Current and deferred tax for the period

Current and deferred tax are recognised as an expense or income in profit or loss, except when they relate to items that are recognised outside profit or loss (whether in other comprehensive income or directly in equity), in which case the tax is also recognised outside profit or loss, or where they arise from the initial accounting for a business combination. In the case of a business combination, the tax effect is included in the accounting for the business combination.

(m) Intangible assets

Intangible assets acquired separately

Intangible assets with finite lives that are acquired separately are carried at cost less accumulated amortisation and accumulated impairment losses. Amortisation is recognised on a straight-line basis over their estimated useful life of 10 years. The estimated useful life and amortisation method are reviewed at the end of each reporting period, with the effect of any changes in estimate being accounted for on a prospective basis. Intangible assets with indefinite useful lives that are acquired separately are carried at cost less accumulated impairment losses.

The following useful lives are used in calculation of amortisation:

- Customer relationships 10 years
- Supplier relationships 10 years

Internally generated intangible assets - research and development expenditure

Expenditure on research activities is recognised as an expense in the period in which it is incurred. Where no internally-generated intangible asset can be recognised, development expenditure is recognised as an expense in the period as incurred. An intangible asset arising from development (or from the development phase of an internal project) is recognised if, and only if, all of the following are demonstrated:

- the technical feasibility of completing the intangible asset so that it will be available for use or sale;
- the intention to complete the intangible asset and use or sell it;
- the ability to use or sell the intangible asset;
- how the intangible asset will generate probable future economic benefits;
- the availability of adequate technical, financial and other resources to complete the development and to use or sell the intangible asset; and
- the ability to measure reliably the expenditure attributable to the intangible asset during its development.

The amount initially recognised for internally-generated intangible assets is the sum of the expenditure incurred from the date when the intangible asset first meets the recognition criteria listed above. Where no internally-generated intangible asset can be recognised, development expenditure is recognised in profit or loss in the period in which it is incurred.

Subsequent to initial recognition, internally-generated intangible assets are reported at cost less accumulated amortisation and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

The following useful lives are used in the calculation of amortisation:

Capitalised development	10 years
-------------------------	----------

Intangible assets acquired in a business combination

Intangible assets acquired in a business combination and recognised separately from goodwill are recognised initially at their fair value at the acquisition date (which is regarded as their cost).

Subsequent to initial recognition, intangible assets acquired in a business combination are reported at cost less accumulated amortisation and accumulated impairment losses, on the same basis as intangible assets that are acquired separately.

De-recognition of intangible assets

An intangible asset is derecognised on disposal, or when no future economic benefits are expected from use or disposal. Gains or losses arising from de-recognition of an intangible asset, measured as the difference between the net disposal proceeds and the carrying amount of the asset are recognised in profit or loss when the asset is derecognised.

3. Material accounting policies (cont'd)

(n) Leases

The Company assesses whether a contract is or contains a lease, at inception of the contract. The Company recognises a right-of-use asset and a corresponding lease liability with respect to all lease arrangements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low value assets. For these leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased assets are consumed.

Lease Liability

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date, discounted by using the rate implicit in the lease. If this rate cannot be readily determined, the Company uses its incremental borrowing rate.

Lease payments included in the measurement of the lease liability comprise:

- Fixed lease payments (including in-substance fixed payments), less any lease incentives receivable
- Variable lease payments that depend on an index or rate, initially measured using the index or rate at the commencement date
- The amount expected to be payable by the lessee under residual value guarantees
- The exercise price of purchase options, if the lessee is reasonably certain to exercise the options
- Payments of penalties for terminating the lease, if the lease term reflects the exercise of an option to terminate the lease.

The lease liability is presented as a separate line in the statement of financial position.

The lease liability is subsequently measured by increasing the carrying amount to reflect interest on the lease liability (using the effective interest method) and by reducing the carrying amount to reflect the lease payments made.

The Group remeasures the lease liability (and makes a corresponding adjustment to the related right-of-use asset) whenever:

- The lease term has changed or there is a significant event or change in circumstances resulting in a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised lease payments using a revised discount rate.
- The lease payments change due to changes in an index or rate or a change in expected payment under a guaranteed residual value, in which cases the lease liability is remeasured by discounting the revised lease payments using an unchanged discount rate (unless the lease payments change is due to a change in a floating interest rate, in which case a revised discount rate is used).
- A lease contract is modified and the lease modification is not accounted for as a separate lease, in which case the lease liability is remeasured based on the lease term of the modified lease by discounting the revised lease payments using a revised discount rate at the effective date of the modification.

The Group did not make any such adjustments during the periods presented.

Right of use asset

The right-of-use assets comprise the initial measurement of the corresponding lease liability, lease payments made at or before the commencement day, less any lease incentives received and any initial direct costs. They are subsequently measured at cost less accumulated depreciation and impairment losses.

Right-of-use assets are depreciated over the shorter period of lease term and useful life of the underlying asset. If a lease transfers ownership of the underlying asset or the cost of the right-of-use asset reflects that the Company expects to exercise a purchase option, the related right-of-use asset is depreciated over the useful life of the underlying asset. The depreciation starts at the commencement date of the lease.

The right-of-use assets are presented as a separate line in statement of financial position.

(o) Inventories

Inventories are valued at the lower of cost and net realisable value. Costs, including an appropriate portion of fixed and variable overhead expenses, are assigned to inventory on hand by the method most appropriate to each particular class of inventory, with the majority being valued on a weighted average cost basis. Net realisable value represents the estimated selling price less all estimated costs of completion and costs to be incurred in marketing, selling and distribution.

(p) Plant and equipment

Plant and equipment are carried at cost less, where applicable, any accumulated depreciation or impairment. Plant and equipment are depreciated over the period of their estimated useful life on a straight-line basis. The estimated useful lives, residual values and depreciation method are reviewed at the end of each annual reporting period. The useful lives adopted for Office Furniture and Equipment is up to 5 years.

3. Material accounting policies (cont'd)

(q) Provisions

Provisions are recognised when the company has a present obligation, the future sacrifice of economic benefits is probable, and the amount of the provision can be measured reliably.

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at reporting date, taking into account the risks and uncertainties surrounding the obligation. Where a provision is measured using the cash flows estimated to settle the present obligation, its carrying amount is the present value of those cash flows.

When some or all of the economic benefits required to settle a provision are expected to be recovered from a third party, the receivable is recognised as an asset if it is virtually certain that recovery will be received and the amount of the receivable can be measured reliably.

(r) Revenue recognition

Sale of goods

Sale of goods is recognised at a point in time when the performance obligations of the sale has been fulfilled and control of the goods has transferred to the customers, which continues to occur at the point of sale when goods were collected or delivered to the premise. In recognising revenue from the sale of goods, the Group considers its historical experience with sales return to determine if it is highly probable that a significant reversal of revenue will arise in the future.

Interest income

Interest income from a financial asset is recognised over time when it is probable that the economic benefits will flow to the company and the amount of revenue can be measured reliably. Interest income is accrued on a time basis, by reference to the principal outstanding and at the effective interest rate applicable, which is the rate that exactly discounts estimated future cash receipts through the expected life of the financial asset to that asset's net carrying amount on initial recognition.

Licence Income

Licence income received from customers in consideration to grant the customer any rights to market and distribute products is recognised either over time or at a point in time, dependent on whether or not the performance obligations are distinct and whether or not this constitutes a right to use or right to access the marketing and distribution right. Where the Group continues to retain the responsibility for the performance obligations associated with the validity of the licence and that the customer simultaneously receives and consumes the benefits from the Group, this is recognised over time. Where the Group provides a right to use the right and is determined to be separable and distinct from other performance obligations within the contract, this is recognised at a point in time. Amounts collected for rights and access not yet provided are recorded as deferred revenue in the statement of financial position.

	Consolidated	
	2025	2024
	\$	\$
4. Profit for the year from continuing operations		
Legal expenses	596,570	449,156
Depreciation of plant and equipment	42,991	39,705
Amortisation of right of use asset	183,395	173,600
Amortisation of intangible assets	2,848,552	2,689,864
Impairment of intangible assets	8,945	609,937
Movement in inventory provision	701,921	(260,191)
Movement in provision for product discounts	(671,138)	149,638
Movement in doubtful debtor provision	(30,238)	(3,150)
Management fees	186,212	176,125
	3,867,210	4,024,684
Employee expenses		
Salaries and wages	6,498,170	6,227,009
Bonuses	616,400	479,200
Superannuation contribution	683,642	670,831
On-cost	482,943	419,723
Other costs	228,669	142,411
	8,509,825	7,939,174
5. Revenue		
Timing of revenue recognition		
Products transferred at point of time	119,388,379	108,550,367
Other Revenue	1,833,714	630,798
Total Revenue	121,222,093	109,181,165
6. Trade and other receivables		
Trade receivables	22,685,708	26,455,804
Provision for doubtful debts	(28,042)	(58,281)
Provision for product discounts	(3,448,547)	(4,119,685)
Provision for grocery terms	(62,926)	(42,814)
	19,146,193	22,235,025
Related party receivables:		
Lupin Australia Pty Ltd	393,330	197,922
Lupin Limited	264,871	11,022
	19,804,394	22,443,968

	Consolidated	
	2025	2024
	\$	\$
7. Inventories		
Finished goods at cost	27,091,251	28,046,111
Provision for slow moving inventory and product expiry	(1,541,612)	(839,691)
	<u>25,549,639</u>	<u>27,206,420</u>
Inventory in transit	11,068,979	7,147,014
	<u>36,618,618</u>	<u>34,353,434</u>
8. Other assets		
Prepaid expenses	334,673	2,367,227
Provision for income tax	512,870	197,524
Restricted Funds	-	379,911
	<u>847,543</u>	<u>2,944,662</u>
9. Goodwill on consolidation		
Goodwill arising on purchase of controlled entity	10,269,000	10,269,000
	<u>10,269,000</u>	<u>10,269,000</u>
10. Office furniture and equipment		
Office furniture and equipment	474,249	415,268
Accumulated depreciation	(383,073)	(340,082)
Total office furniture and equipment – written down value	<u>91,176</u>	<u>75,186</u>
	Total Office Furniture and equipment	
	\$	
Cost		
Balance at 1 April 2024	415,268	
Additions	58,981	
Disposals	-	
	<u>474,249</u>	
Balance at 31 March 2025	<u>474,249</u>	
Accumulated depreciation		
Balance at 1 April 2024	340,082	
Depreciation	42,991	
Disposals	-	
	<u>383,073</u>	
Balance at 31 March 2025	<u>383,073</u>	
Carrying amount as at 31 March 2025	<u>91,176</u>	
	<u>91,176</u>	
Carrying amount as at 31 March 2024	<u>75,186</u>	
	<u>75,186</u>	

The useful life of office furniture and equipment is 5-15 years.

Consolidated	
2025	2024
\$	\$

11. Intangible assets

Capitalised product development costs	38,280,755	37,236,366
Accumulated amortisation and impairment	(19,648,547)	(16,799,997)
	18,632,208	20,436,369
Capitalised product development costs – not yet available for sale	2,678,655	2,336,330
	21,310,863	22,772,699

	Capitalised product development costs	Capitalised product development costs – not yet available for use	Customer relationships	Supplier Contracts	Acquired products yet be registered	Total
	\$	\$	\$	\$	\$	\$
Cost						
Balance at 1 April 2024	13,913,458	1,256,571	15,571,144	7,751,764	1,079,759	39,572,696
Transfers	902,031	(902,031)	-	7,695	(7,695)	-
Additions	143,609	1,252,052	-	-	-	1,395,661
Impairment expense	(1,250)	-	-	(7,695)	-	(8,945)
Balance at 31 March 2025	14,957,848	1,606,592	15,571,144	7,751,764	1,072,064	40,959,412
Accumulated depreciation						
Balance at 1 April 2024	11,893,082	-	3,345,586	1,561,329	-	16,799,997
Disposals	-	-	-	-	-	-
Depreciation expense	510,225	-	1,563,142	775,185	-	2,848,552
Balance at 31 March 2025	12,403,307	-	4,908,728	2,336,514	-	19,648,549
Carrying amount as at 31 March 2025	2,554,541	1,606,592	10,662,416	5,415,250	1,072,064	21,310,863
Carrying amount as at 31 March 2024	2,020,376	1,256,571	12,225,558	6,190,435	1,079,759	22,772,699

	Consolidated	
	2025	2024
	\$	\$
12. Right of use asset		
Gross Block	1,242,560	1,210,198
Less: Accumulated amortisation	(1,023,488)	(840,092)
	219,072	370,106

	Buildings	Office Equipment	Total
Balance as at 1st April 2024	361,093	9,013	370,106
Additions	31,439	922	32,361
Depreciation	(179,716)	(3,680)	(183,395)
Balance as at 31st March 2025	212,817	6,255	219,072

13. Trade and other payables

Trade payables	7,085,970	9,328,922
Sundry creditors and accruals	3,408,969	5,425,392
Employee bonus	357,348	350,059
Other	21,574	21,575
Related party payables:		
Lupin Limited	6,720,957	6,373,803
Lupin Management Inc	54,010	34,507
Lupin Atlantis Holdings SA	-	-
Lupin Australia Pty Ltd	500	19,805
Lupin Inc.	216,598	453,938
	17,865,926	22,008,001

The Group has financial risk management policies in place to ensure that all payables are paid within the pre-agreed credit terms.

14. Related party transactions

14.1 Trading transactions

During the year, the Company entered into the following trading transactions with related parties:

- Stock purchases during the financial year from Lupin Limited amounted to \$14,516,355 (FY24: \$16,065,727)
- Stock purchases during the financial year from Lupin Inc amounted to \$216,598 (FY24: \$453,938)
- Legal and professional fees paid to Lupin Ltd amounted to \$258,438 (FY24: \$153,844)
- Royalty paid to Lupin Australia Ltd amounted to \$1,956 (FY24: \$5,212)
- Management fee paid to amounted to \$186,212 (FY24: \$176,125)

		Consolidated	
		2025	2024
		\$	\$
15. Borrowings			
<u>Current</u>			
Escrow contract liability	(i)	-	379,911
		-	379,911
<u>Non- Current</u>			
Deferred Consideration		400,000	1,200,000
		400,000	1,200,000
16. Lease Liability			
<u>Current</u>			
Lease Liability		240,546	214,924
<u>Non- Current</u>			
Lease Liability		79,887	298,241
Amounts recognised in profit and loss			
Interest expense in lease liability		11,500	18,126
Depreciation expense on right-of-use-assets		183,395	173,600
17. Provisions			
<u>Current</u>			
Employee benefit		1,311,513	1,281,962
<u>Non-current</u>			
Employee benefits		118,757	66,184
18. Issued capital			
207,100,371 fully paid ordinary shares (2024:			
207,100,371)		33,883,471	33,883,471

Fully paid ordinary shares carry one vote per share and carry the right to dividends.

Changes to the then Corporations Law abolished the authorised capital and par value concept in relation to share capital from 1 July 1998. Therefore, the company does not have a limited amount of authorised capital and issued shares do not have a par value.

Consolidated	
2025	2024
\$	\$

19. Subsequent events

No matter or circumstance has occurred subsequent to year end that has significantly affected, or may significantly affect, the operations of the Company, the results of those operations or the state of affairs of the entity in subsequent financial years.

20. Controlled entities

	Country of Incorporation	Percentage owned	
		2025	2024
Subsidiaries of Generic Health Pty Ltd:			
Southern Cross Pharma Pty Ltd	Australia	100%	100%
Lupin NZ Ltd	New Zealand	100%	-

21. Cash and cash equivalents

(a) Reconciliation of cash and cash equivalents

For the purposes of the statement of cash flows, cash and cash equivalents includes cash on hand and in banks and investments in money market instruments, net of outstanding bank overdrafts. Cash and cash equivalents at the end of the financial year as shown in the statement of cash flows can be reconciled to the related items in the statement of financial position as follows:

	Consolidated	
	2025	2024
	\$	\$
Cash on hand	-	-
Cash at bank	21,839,935	9,910,208
Total cash and cash equivalents	21,839,935	9,910,208

(i) AUD \$16,000,000 Term deposits (2024: 13,500,000) are less than 30 days to maturity

Consolidated	
2025	2024
\$	\$

22. Income tax benefit recognised in profit and loss

Current and deferred tax

In respect of the current year

Current Year

- Current year	7,867,807	6,124,528
- Adjustment for Prior Year	164,415	259,242

Deferred Tax Expense (income) relating to

- Origination and reversal of temporary difference	(1,376,061)	(131,491)
- Adjustment for current tax in respect of prior year	(183,219)	23,417

	6,472,942	6,275,696
--	-----------	-----------

23. Income tax relating to continuing operations

Profit before tax from continuing operations	21,326,154	19,538,868
Prima facie income tax expense (at 30%)	6,397,846	5,861,660
Permanent differences	63,225	240,772
Temporary differences	-	22,096
Change in recognised deferred tax assets	-	(108,073)
Other	11,871	259,241
Income tax expense recognised in profit or loss (from continuing operations)	6,472,942	6,275,696

Imputation credits (Franking credits)

Franking Account balance as of 31 st March	5,612,514	5,612,514
Imputation Credits that will arise from the payment of current tax liability	-	-

24. Deferred tax balances

Deferred tax assets	2,110,993	1,255,520
Deferred Tax Liability on Acquisition of Southern Cross Pharma	5,144,918	(5,848,725)
	(3,033,925)	(4,593,205)

No deferred tax asset has been recognised for the tax losses incurred by Lupin NZ Limited during the year.

Consolidated			
	2025	2024	
	\$	\$	
2025	Opening balance	Recognised in profit and loss	Closing balance
Temporary differences			
Inventory provision	251,907	210,577	462,484
Claims Provision	188,873	243,604	432,477
Employee related provisions	404,444	149,136	553,580
Trade and other payable	377,068	249,107	626,175
Unrealised foreign exchange	-	9,686	9,686
Intangible assets	(5,848,725)	703,807	(5,144,918)
Leases liability	153,951	(58,061)	95,890
Other assets	(6,169)	2,315	(3,854)
Blackhole s25-25 assets	(16,996)	16,996	-
Right of use asset	(113,125)	47,680	(65,445)
Other	15,567	(15,567)	-
	(4,593,205)	1,559,280	(3,033,925)

26. Parent entity information

The accounting policies of the parent entity, which have been applied in determining the financial information shown below, are the same as those applied in the consolidated financial statements except as set out below. Refer to note 3 for a summary of the significant accounting policies relating to the Group.

Financial position

Assets

Current assets	48,585,592	49,914,067
Non-current assets	38,100,257	36,133,266
Total assets	86,685,849	86,047,333

Liabilities

Current liabilities	14,704,239	18,134,725
Non-current liabilities	525,728	1,564,427
Total liabilities	15,229,967	19,699,152

Equity

Issued capital	33,883,471	33,883,471
Retained earnings	37,572,411	32,464,710
Total equity	71,455,882	66,348,181

Financial performance

Profit for the year	5,496,441	6,918,736
Dividend income	-	5,000,000
Total comprehensive income	5,496,441	11,918,736

27. Financial Instruments

Consolidated	
2025	2024
\$	\$

The Group holds the following financial instruments:

Financial assets – amortised cost

Cash and bank balances	21,789,179	9,910,208
Trade and other receivables	20,317,264	22,641,492
Deposits>90 days	50,756	-
Prepayments	4,599,748	2,747,138
	<u>46,756,947</u>	<u>35,298,838</u>

Financial liabilities – amortised cost

Trade and other payables	17,865,925	22,008,001
Borrowings with external parties	-	-
Deferred consideration	400,000	1,200,000
Escrow contract liability	-	379,911
	<u>18,265,925</u>	<u>23,587,912</u>

28. Contingent liabilities

No contingent liabilities exist as at the date of this report.

29. Compensation of Key Management Personnel

The remuneration of directors and other members of key management personnel during the year was as follows:

Short-term benefits	1,346,029	1,230,625
Other long-term benefits		49,856
	<u>1,346,029</u>	<u>1,280,481</u>

30. Remuneration of the Auditors

Audit or review of financial reports:

- Group	(ii)	104,383	64,050
---------	------	---------	--------

Statutory assurance services required by legislation to be provided by the auditors

- Group	-	93,925
---------	---	--------

Other services	56,215	150,667
----------------	--------	---------

	<u>160,598</u>	<u>308,642</u>
--	----------------	----------------

(ii) Relates to special purpose quarterly audit review reports

Approval of financial statements

The financial statements were approved by the board of directors and authorised for issue on 6 May 2025.